Big players in the LAMA/LABA fixed-dose combinations I'm aware of are: GSK, NVS, FRX, AZN and B-I.
GSK's anoro should be the first-to-market in the US, about a year ahead of NVS's QVA149. NVS should be first in EU, but GSK is very close behind.
Except for timing, GSK/THRX highlighted another advantage - triple (LAMA/LABA/steroid) delivery with their device. A single device with once daily dosing (FRX twice daily could still be a better choice for patients requiring a second dose before bedtime), may provide a significant advantage, potentially improving adherence and patient outcomes. However, FRX's Pressair, NVS's Breezhaler and GSK's Ellipta, all belong to the same type of delivery device (dry powder inhaler), so I presume that triple delivery could work with all of them (AZN/Pearl’s and B-I's devices are of a different type).
All in all, it's a big market and FRX should be able to capture a few hundred M piece even as a minor player.
